drugset / Trial / NCT00192777

Concurrent Xeloda and Radiotherapy for Bone Metastases

NCT00192777 ↗

Phase 2 Unknown 20 enrolled Rambam Health Care Campus
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Hypothesis: Radiosensitization using Xeloda should improve the rate of complete pain relief. Primary Objective: * To determine the frequency of pain relief for the proposed regimen. Secondary Objective(s): * To determine the duration of pain relief and narcotic relief for the proposed regimen. * To determine the frequency of narcotic relief for the proposed regimen. * To determine the toxicity of concurrent UFT and radiotherapy in patients with bone metastases.

Timeline

Start
2004-11
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule — —

Indications